Prodrug approaches to reduce hyperexcitation in the CNS

Advanced Drug Delivery Reviews

Volumn 64, Issue 7, 2012, Pages 666-685

  Vytla, Devaiah ^a   Combs Bachmann, Rosamund E ^a   Hussey, Amanda M ^a   McCarron, Stephen T ^a   McCarthy, Devon S ^a   Chambers, James J ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Alzheimer's disease; CNS prodrug; Hyperexcitation prodrug; Receptors; Stroke; Targeting

Indexed keywords

ALZHEIMER'S DISEASE; PRODRUGS; RECEPTORS; STROKE; TARGETING;

DRUG DELIVERY; MEDICINE;

BIOMEDICAL ENGINEERING;

4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; 7 CHLOROKYNURENIC ACID; ADRENERGIC RECEPTOR; ANTICONVULSIVE AGENT; CALCIUM CHANNEL; CARBAMAZEPINE; CARBIDOPA PLUS LEVODOPA; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMATE RECEPTOR ANTAGONIST; IONOTROPIC RECEPTOR; LEVODOPA; MEMANTINE; METABOTROPIC RECEPTOR; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; PLACEBO; POTASSIUM CHANNEL; PRODRUG; REMACEMIDE; RILUZOLE; SODIUM CHANNEL; TEZAMPANEL; TOPIRAMATE; TRAXOPRODIL; UNINDEXED DRUG; VALPROIC ACID;

ABDOMINAL PAIN; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BIPOLAR MANIA; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CALCIUM TRANSPORT; CENTRAL NERVOUS SYSTEM; DIZZINESS; DROWSINESS; DRUG DESIGN; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG TRANSPORT; DYSKINESIA; EPILEPSY; EXCITATION; EXCITOTOXICITY; FOCAL EPILEPSY; GABAERGIC TRANSMISSION; GASTROINTESTINAL SYMPTOM; GRAND MAL SEIZURE; HEAT SENSATION; HUMAN; HUNTINGTON CHOREA; HYPEREXCITATION; LIVER DISEASE; MIGRAINE; NAUSEA; NONHUMAN; OPIATE ADDICTION; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SECOND MESSENGER; SEDATION; SEIZURE; SEIZURE THRESHOLD; SIDE EFFECT; SPREADING CORTICAL DEPRESSION; SYNAPSE; SYNAPTIC TRANSMISSION; TEMPORAL LOBE EPILEPSY; TONIC CLONIC SEIZURE; TRIGEMINUS NEURALGIA;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; PRODRUGS; PSYCHOMOTOR AGITATION;

EID: 84859964344     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.11.007     Document Type: Review

References (149)

1. Szydlowska K., Tymianski M. Calcium, ischemia and excitotoxicity. Cell Calcium 2010, 47:122-129.
2. Stanika R.I., Pivovarova N.B., Brantner C.A., Watts C.A., Winters C.A., Andrews S.B. Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicity. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:9854-9859.
3. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 2010, 11:682-696.
4. DeFelipe J., Alonso-Nanclares L., Arellano J.I. Microstructure of the neocortex: comparative aspects. J. Neurocytol. 2002, 31:299-316.
5. Lau A., Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflügers Arch. 2010, 460:525-542.
6. von Engelhardt J., Coserea I., Pawlak V., Fuchs E.C., Köhr G., Seeburg P.H., Monyer H. Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptors. Neuropharmacology 2007, 53:10-17.
7. Enz R., Cutting G.R. Molecular composition of GABAC receptors. Vision Res 1998, 38:1431-1441.
8. Mitchell S.J., Silver R.A. Shunting inhibition modulates neuronal gain during synaptic excitation. Neuron 2003, 38:433-445.
9. Czuczwar S.J., Patsalos P.N. The new generation of GABA enhancers: potential in the treatment of epilepsy. CNS Drugs 2001, 15.
10. Dichter M.A., Brodie M.J. New antiepileptic drugs. N. Engl. J. Med. 1996, 334:1583-1590.
11. Meldrum B.S., Rogawski M.A. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007, 4:18-61.
12. White H.S., Smith M.D., Wilcox K.S. Mechanisms of action of antiepileptic drugs. The Neurobiology of Epilepsy and Aging 2007, Volume 81:85-110.
13. Yellen G. The moving parts of voltage-gated ion channels. Q. Rev. Biophys. 1998, 31:239-295.
14. Maljevic S., Wuttke T.V., Lerche H. Nervous system KV7 disorders: breakdown of a subthreshold brake. J. Physiol. 2008, 586:1791-1801.
15. Miceli F., Soldovieri M.V., Martire M., Taglialatela M. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs. Curr. Opin. Pharmacol. 2008, 8:65-74.
16. Schroder R.L., Jespersen T., Christophersen P., Strobaek D., Jensen B.S., Olesen S.P. KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology 2001, 40:888-898.
17. Wickenden A.D., Yu W., Zou A., Jegla T., Wagoner P.K. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol. Pharmacol. 2000, 58:591-600.
18. Levinson S. Sodium Channels. Encyclopedia of Neuroscience 2008, 3759-3766. Springer, Berlin. M. Binder, N. Hirokawa, U. Windhorst (Eds.).
19. Mantegazza M., Curia G., Biagini G., Ragsdale D.S., Avoli M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological diseases. Lancet Neurol. 2010, 9:413-424.
20. Dolmetsch R.E., Pajvani U., Fife K., Spotts J.M., Greenberg M.E. Signaling to the nucleus by an L-type calcium channel-calmodulin complex through the MAP kinase pathway. Science 2001, 294:333-339.
21. Fields R.D., Lee P.R., Cohen J.E. Temporal integration of intracellular Ca2+ signaling networks in regulating gene expression by action potentials. Cell Calcium 2005, 37:433-442.
22. Sutton K.G., McRory J.E., Guthrie H., Murphy T.H., Snutch T.P. P/Q-type calcium channels mediate the activity-dependent feedback of syntaxin-1A. Nature 1999, 401:800-804.
23. Seagar M., Takahashi M. Interactions between presynaptic calcium channels and proteins implicated in synaptic vesicle trafficking and exocytosis. J. Bioenerg. Biomembr. 1998, 30:347-356.
24. Spafford J.D., van Minnen J., Larsen P., Smit A.B., Syed N.I., Zamponi G.W. Uncoupling of calcium channel α1 and β subunits in developing neurons. J. Biol. Chem. 2004, 279:41157-41167.
25. Wheeler D.B., Randall A., Tsien R.W. Changes in action potential duration alter reliance of excitatory synaptic transmission on multiple types of Ca2+ channels in rat hippocampus. J. Neurosci. 1996, 16:2226-2237.
26. Perez-Reyes E. Molecular physiology of low-voltage-activated T-type calcium channels. Physiol. Rev. 2003, 83:117-161.
27. Catterall W.A., Perez-Reyes E., Snutch T.P., Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol. Rev. 2005, 57:411-425.
28. Wu L.G., Saggau P. GABAB receptor-mediated presynaptic inhibition in guinea-pig hippocampus is caused by reduction of presynaptic Ca2+ influx. J. Physiol. 1995, 485:649-657.
29. Dittman J.S., Regehr W.G. Contributions of calcium-dependent and calcium-independent mechanisms to presynaptic inhibition at a cerebellar synapse. J. Neurosci. 1996, 16:1623-1633.
30. Thompson S.M., Gähwiler B.H. Comparison of the actions of baclofen at pre- and postsynaptic receptors in the rat hippocampus in vitro. J. Physiol. 1992, 451:329-345.
31. Chalifoux J.R., Carter A.G. GABAB receptor modulation of voltage-sensitive calcium channels in spines and dendrites. J. Neurosci. 2011, 31:4221-4232.
32. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78:189-225.
33. Beaulieu J.-M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011, 63:182-217.
34. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 2006, 5:160-170.
35. Ballard C., Gauthier S., Corbett A., Brayne C., Aarsland D., Jones E. Alzheimer's disease. Lancet 2011, 377:1019-1031.
36. Gouras G., Tampellini D., Takahashi R., Capetillo-Zarate E. Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol. 2010, 119:523-541.
37. Li S., Hong S., Shepardson N.E., Walsh D.M., Shankar G.M., Selkoe D. Soluble oligomers of amyloid [beta] protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62:788-801.
38. N.-W. Hu, T. Ondrejcak, M.J. Rowan, Glutamate receptors in preclinical research on Alzheimer's disease: Update on recent advances, Pharmacology Biochemistry and Behavior, in press, Corrected Proof.
39. Mony L., Kew J.N.C., Gunthorpe M.J., Paoletti P. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br. J. Pharmacol. 2009, 157:1301-1317.
40. Okamoto S.-i., Pouladi M.A., Talantova M., Yao D., Xia P., Ehrnhoefer D.E., Zaidi R., Clemente A., Kaul M., Graham R.K., Zhang D., Vincent Chen H.S., Tong G., Hayden M.R., Lipton S.A. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 2009, 15:1407-1413.
41. Milnerwood A.J., Gladding C.M., Pouladi M.A., Kaufman A.M., Hines R.M., Boyd J.D., Ko R.W.Y., Vasuta O.C., Graham R.K., Hayden M.R., Murphy T.H., Raymond L.A. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010, 65:178-190.
42. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10:83-98.
43. Meissner W.G., Frasier M., Gasser T., Goetz C.G., Lozano A., Piccini P., Obeso J.A., Rascol O., Schapira A., Voon V., Weiner D.M., Tison F., Bezard E. Priorities in Parkinson's disease research. Nat. Rev. Drug Discov. 2011, 10:377-393.
44. Koutsilieri E., Riederer P. Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease. Parkinsonism Relat. Disord. 2007, 13:S329-S331.
45. Calabresi P., Di Filippo M., Ghiglieri V., Tambasco N., Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol. 2010, 9:1106-1117.
46. Poewe W., Antonini A., Zijlmans J.C.M., Vingerhoets F. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin. Interv. Aging 2010, 5:229-238.
47. Kwak S., Hideyama T., Yamashita T., Aizawa H. AMPA receptor-mediated neuronal death in sporadic ALS. Neuropathology 2010, 30:182-188.
48. Zinman L., Cudkowicz M. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol. 2011, 10:481-490.
49. Sierra-Paredes G., Sierra-Marcuno G. Extrasynaptic GABA and glutamate receptors in epilepsy. CNS Neurol. Disord. Drug Targets 2007, 6:288-300.
50. van Luijtelaar G., Sitnikova E. Global and focal aspects of absence epilepsy: the contribution of genetic models. Neurosci. Biobehav. Rev. 2006, 30:983-1003.
51. Snead O.C. Pharmacological models of generalized absence seizures in rodents. J. Neural Transm. Suppl. 1992, 35:7-19.
52. Coulter D.A., McIntyre D.C., Löscher W. Animal models of limbic epilepsies: what can they tell us?. Brain Pathol. 2002, 12:240-256.
53. Lagrange A.H., Botzolakis E.J., Macdonald R.L. Enhanced macroscopic desensitization shapes the response of α4 subtype-containing GABAA receptors to synaptic and extrasynaptic GABA. J. Physiol. 2007, 578:655-676.
54. Chang B.S., Lowenstein D.H. Epilepsy. N. Engl. J. Med. 2003, 349:1257-1266.
55. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 2000, 342:314-319.
56. Khosravani H., Zamponi G.W. Voltage-gated calcium channels and idiopathic generalized epilepsies. Physiol. Rev. 2006, 86:941-966.
57. Moskowitz M.A. Pathophysiology of headache-past and present. Headache 2007, 47(Suppl. 1):S58-63.
58. Goadsby P.J., Hoskin K.L., Storer R.J., Edvinsson L., Connor H.E. Adenosine A1 receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 2002, 125:1392-1401.
59. Ambrosini A., de Noordhout A.M., Sándor P.S., Schoenen J. Electrophysiological studies in migraine: a comprehensive review of their interest and limitations. Cephalalgia 2003, 23:13-31.
60. Welch K.M. Brain hyperexcitability: the basis for antiepileptic drugs in migraine prevention, headache. J. Head Face Pain 2005, 45:S25-S32.
61. Scheller D., Szathmary S., Kolb J., Tegtmeier F. Observations on the relationship between the extracellular changes of taurine and glutamate during cortical spreading depression, during ischemia, and within the area surrounding a thrombotic infarct. Amino Acids 2000, 19:571-583.
62. Lauritzen M., Hansen A.J. The effect of glutamate receptor blockade on anoxic depolarization and cortical spreading depression. J. Cereb. Blood Flow Metab. 1992, 12:223-229.
63. Mody I., Lambert J.D., Heinemann U. Low extracellular magnesium induces epileptiform activity and spreading depression in rat hippocampal slices. J. Neurophysiol. 1987, 57:869-888.
64. Gorji A. Spreading depression: a review of the clinical relevance. Brain Res. Rev. 2001, 38:33-60.
65. Vikelis M., Mitsikostas D.D. The role of glutamate and its receptors in migraine. CNS Neurol. Disord. Drug Targets 2007, 6:251-257.
66. Rogawski M.A. Common pathophysiologic mechanisms in migraine and epilepsy. Arch. Neurol. 2008, 65:709-714.
67. Weiss B., Alt A., Ogden A.M., Gates M., Dieckman D.K., Clemens-Smith A., Ho K.H., Jarvie K., Rizkalla G., Wright R.A., Calligaro D.O., Schoepp D., Mattiuz E.L., Stratford R.E., Johnson B., Salhoff C., Katofiasc M., Phebus L.A., Schenck K., Cohen M., Filla S.A., Ornstein P.L., Johnson K.W., Bleakman D. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. J. Pharmacol. Exp. Ther. 2006, 318:772-781.
68. Rosenfeld W.E. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin. Ther. 1997, 19:1294-1308.
69. Pavan B., Dalpiaz A., Ciliberti N., Biondi C., Manfredini S., Vertuani S. Progress in drug delivery to the central nervous system by the prodrug approach. Molecules 2008, 13:1035-1065.
70. Ricci M., Blasi P., Giovagnoli S., Rossi C. Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue?. Curr. Med. Chem. 2006, 13:1757-1775.
71. Pardridge W.M. Blood-brain barrier delivery. Drug Discov. Today 2007, 12:54-61.
72. Alam M.I., Beg S., Samad A., Baboota S., Kohli K., Ali J., Ahuja A., Akbar M. Strategy for effective brain drug delivery. Eur. J. Pharmacol. 2010, 40:385-403.
73. Rautio J., Kumpulainen H., Heimbach T., Oliyai R., Oh D., Jarvinen T., Savolainen J. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 2008, 7:255-270.
74. Majumdar S., Sloan K.B. Synthesis, hydrolyses and dermal delivery of N-alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) derivatives of phenol, imide and thiol containing drugs. Bioorg. Med. Chem. Let. 2006, 16:3590-3594.
75. Peyrottes S., Egron D., Lefebvre I., Gosselin G., Imbach J.L., Perigaud C. SATE pronucleotide approaches: an overview. Mini Rev. Med. Chem. 2004, 4:395-408.
76. Fozard J. BP-294 Ste Civile Bioprojet. Curr. Opin. Investig. Drugs 2000, 1:86-89.
77. Simplicio A.L.s., Clancy J.M., Gilmer J.F. [beta]-Aminoketones as prodrugs with pH-controlled activation. Int. J. Pharm. 2007, 336:208-214.
78. Rautio J., Laine K., Gynther M., Savolainen J. Prodrug approaches for CNS delivery. AAPS J. 2008, 10:92-102.
79. Beaumont K., Webster R., Gardner I., Dack K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr. Drug Metab. 2003, 4:461-485.
80. Rautio J. Prodrugs and Targeted Delivery: Towards Better ADME Properties 2011, 520. Wiley. R. Mannhold, H. Kubinyi, G. Folkers (Eds.).
81. Yang C., Tirucherai G.S., Mitra A.K. Prodrug based optimal drug delivery via membrane transporter/receptor. Expert. Opin. Biol. Ther. 2001, 1:159-175.
82. Cundy K.C., Branch R., Chernov-Rogan T., Dias T., Estrada T., Hold K., Koller K., Liu X., Mann A., Panuwat M., Raillard S.P., Upadhyay S., Wu Q.Q., Xiang J.-N., Yan H., Zerangue N., Zhou C.X., Barrett R.W., Gallop M.A. XP13512 [(±)-1-([(α-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane Acetic Acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J. Pharmacol. Exp. Ther. 2004, 311:315-323.
83. Goldenberg G.J., Lam H.Y., Begleiter A. Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro. J. Biol. Chem. 1979, 254:1057-1064.
84. Gomes P., Soares-da-Silva P. DOPA transport properties in an immortalised cell line of rat capillary cerebral endothelial cells, RBE 4. Brain Res. 1999, 829:143-150.
85. Mena I., Cotzias G.C. Protein intake and treatment of Parkinson's Disease with Levodopa. N. Engl. J. Med. 1975, 292:181-184.
86. Stone T.W. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol. Sci. 2000, 21:149-154.
87. Bonina F.P., Arenare L., Ippolito R., Boatto G., Battaglia G., Bruno V., de Caprariis P. Synthesis, pharmacokinetics and anticonvulsant activity of 7-chlorokynurenic acid prodrugs. Int. J. Pharm. 2000, 202:79-88.
88. Ooie T., Terasaki T., Suzuki H., Sugiyama Y. Kinetic evidence for active efflux transport across the blood-brain Barrier of Quinolone antibiotics. J. Pharmacol. Exp. Ther. 1997, 283:293-304.
89. Polli J.W., Jarrett J.L., Studenberg S.D., Humphreys J.E., Dennis S.W., Brouwer K.R., Woolley J.L. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. 1999, 16:1206-1212.
90. Deguchi Y., Hayashi H., Fujii S., Naito T., Yokoyama Y., Yamada S., Kimura R. Improved brain delivery of a nonsteroidal anti-inflammatory drug with a synthetic glyceride ester: a preliminary attempt at a CNS drug delivery system for the therapy of Alzheimer's disease. J. Drug Target. 2000, 8:371-381.
91. Misra A., Ganesh S., Shahiwala A., Shah S.P. Drug delivery to the central nervous system: a review. J. Pharm. Pharm. Sci. 2003, 6:252-273.
92. Soni V., Kohli D.V., Jain S.K. Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J. Drug Target. 2008, 16:73-78.
93. Blasi P., Giovagnoli S., Schoubben A.l., Ricci M., Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev. 2007, 59:454-477.
94. Kaur I.P., Bhandari R., Bhandari S., Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J. Control. Release 2008, 127:97-109.
95. Liu L., Venkatraman S.S., Yang Y.-Y., Guo K., Lu J., He B., Moochhala S., Kan L. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier. Pept. Sci. 2008, 90:617-623.
96. Dhanikula R.S., Argaw A., Bouchard J.-F., Hildgen P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol. Pharm. 2008, 5:105-116.
97. Labiner D. DP-VPA DPharma. Curr. Opin. Investig. Drugs 2002, 3:921-923.
98. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?. Cell Mol. Life Sci. 2007, 64:2090-2103.
99. Rosenberg G., Friedman J., Shapiro I., Koazk A. DP-VPA: an antiepileptic drug. Drugs Future 2005, 30:1212-1218.
100. Trojnar M., Wierzchowski-Cioch E., Krzyzanowski M., Jargiello M., Czuczwar S. New generation of valproic acid. Pol. J. Pharmacol. 2004, 56:283-288.
101. Chaki S., Yoshikawa R., Hirota S., Shimazaki T., Maeda M., Kawashima N., Yoshimizu T., Yasuhara A., Sakagami K., Okuyama S., Nakanishi S., Nakazato A. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 2004, 46:457-467.
102. Chaki S., Okuyama S. Neuropeptide receptors: novel therapeutic targets for depression. Nihon Yakurigaku Zasshi 2006, 127:196-200.
103. Nakamura M., Kawakita Y., Yasuhara A., Fukasawa Y., Yoshida K., Sakagami K., Nakazato A. In vitro and in vivo evaluation of the metabolism and bioavailability of ester prodrugs of MGS0039 (3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo [3.1.0]hexane-2,6-dicarboxylic acid), a potent metabotropic glutamate receptor antagonist. Drug Metab. Dispos. 2006, 34:369-374.
104. Yasuhara A., Nakamura M., Sakagami K., Shimazaki T., Yoshikawa R., Chaki S., Ohta H., Nakazato A. Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarbo xylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential. Bioorg. Med. Chem. 2006, 14:4193-4207.
105. Gilron I. LY-293558 Eli Lily & Co. Curr. Opin. Investig. Drugs 2001, 2:1273-1278.
106. McLemore G., Kest B., Inturrisi C. The effects of LY293558, an AMPA receptor antagonist, on acute and chronic morphine dependence. Brain Res. 1997, 120-126.
107. Sang C., Ramadan N., Wallihan A., Chappell F., Freitag T., Smith S., Silberstein K., Johnson L., Phebus D. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004, 24:596-602.
108. Carlezon W., Rasmussen K., Nestler E. AMPA antagonist LY293558 blockas the development, without blocking the expression, of behavioral sensitization to morphine. Synapse 1999, 31:256-262.
109. Rasmussen K., Kendrick W., Kogan J. A selective AMPA antagonist Ly293558, suppresses morphine withdrawal-induced activation of locus coerules neurons and behavioral signs. Neuropsychopharmacology 1996, 15:497-505.
110. Dominguez E., Iyengar S., Shannon H.E., Bleakman D., Alt A., Arnold B.M., Bell M.G., Bleisch T.J., Buckmaster J.L., Castano A.M., Del Prado M., Escribano A., Filla S.A., Ho K.H., Hudziak K.J., Jones C.K., Martinez-Perez J.A., Mateo A., Mathes B.M., Mattiuz E.L., Ogden A.M., Simmons R.M., Stack D.R., Stratford R.E., Winter M.A., Wu Z., Ornstein P.L. Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain. J. Med. Chem. 2005, 48:4200-4203.
111. Rektorova I. Therapy for idiopathic Parkinson's Disease 2002, European Parkinsons disease Association.
112. Sneader W. Drug Discovery a History 2005, Wiley.
113. Goole J., Amighi K. Levodopa delivery systems for the treatment of Parkinson's disease. Int. J. Pharm. 2009, 1-15.
114. Tsuji A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2005, 2:54-62.
115. Factor S., Weiner W. Parkinson's Disease: Diagnosis and Clinical Management, New York 2002.
116. Goldstein D.S. L-dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc. Drug Rev. 2006, 24:189-203.
117. Goldstein D.S., Holmes C., Kaufmann H., Freeman R. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin. Auton. Res. 2004, 14:363-368.
118. Accessed Aug 1, 2011. http://clinicaltrials.gov/ct2/show/NCT00633880.
119. Pynnönen S. Pharmacokinetics of carbamazepine in man: a review. Ther. Drug Monit. 1979, 1:409-431.
120. Albani F., Riva R., Baruzzi B. Carbamazepine clinical pharmacology: a review. Pharmacopsychiatry 1995, 28:235-244.
121. Ambrósio A., Soares-da-Silva P., Carvalho C., Carvalho A. Mechanisms of action of carbamazepine and its derivatives, oxacarbazepine, BIA 2-093, and BIA 2-024. Neurochem. Res. 2002, 27:121-130.
122. Levy R.H. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995, 36(Suppl. 5):S8-13.
123. Loiseau P., Duche B., Pedespan J.M. Absence epilepsies. Epilepsia 1995, 36:1182-1186.
124. Caraiscos V.B., Elliott E.M., You-Ten K.E., Cheng V.Y., Belelli D., Newell J.G., Jackson M.F., Lambert J.J., Rosahl T.W., Wafford K.A., MacDonald J.F., Orser B.A. Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by α5 subunit-containing γ-aminobutyric acid type A receptors. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3662-3667.
125. Brewster M.E., Anderson W.R., Estes K.S., Bodor N. Development of aqueous parenteral formulations for carbamazepine through the use of modified cyclodextrins. J. Pharm. Sci. 1991, 80:380-383.
126. Hemenway J.N., Stella V.J. In vitro and in vivo evaluation of a novel water-soluble N-glycyl prodrug (N-GLY-CBZ) of carbamazepine. J. Pharm. Sci. 2010, 99:4565-4575.
127. J.H. Block, J.M. Beale Jr., Wilson and Gisvold's Textbook of Organic, Medicinal and Pharmaceutical Chemistry, in, Lippincott, Williams and Wilkins, Philadelphia, 2004, pp. 991.
128. Spina E., Pisani F., Perucca E. Clincially significant pharmacokinetic drug interactions with carbamazepine. Clin. Pharamcokinet. 1996, 31:198-214.
129. Asadi-Pooya A.A., Sperling M.R. Antieplieptic drugs: a clincian's manual 2009, Oxford University Press, New York, NY.
130. Macdonald R.L., Kelly K.M. Antiepileptic drug mechanisms of action. Epilepsia 1995, 36:s2-s12.
131. Willow M., Kuenzel E.A., Catterall W.A. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol. Pharmacol. 1984, 25:228-234.
132. Ambrosio A.F., Silva A.P., Malva J.O., Soares-da-Silva P., Carvalho A.P., Carvalho C.M. Carbamazepine inhibits L-type Ca2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists. Neuropharmacology 1999, 38:1349-1359.
133. Basselin M., Villacreses N.E., Chen M., Bell J.M., Rapoport S.I. Chronic carbamazepine administration reduces N-methyl-d-aspartate receptor-initiated signaling via arachidonic acid in rat brain. Biol. Psychiatry 2007, 62:934-943.
134. Zhou S., Chan E., Pan S.Q., Huang M., Lee E.J.D. Pharmacokinetic interactions of drugs with St. John's wort. J. Psychopharmacol. 2004, 18:262-276.
135. Carbamazepine, in, Information updated 01 Sept 2009, accessed 13 July 2011.
136. Tomson T., Battino D., Bonizzoni E., Craig J., Lindhout D., Sabers A., Perucca E., Vajda F. Dose-dependant risk of malformation with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011, 10:609-617.
137. Stella V. A case for prodrugs: fosphenytonin. Adv. Drug Deliv. Rev. 1996, 19:311-330.
138. Stella V. Fosphenytonin: a prodrug of phenytonin. Prodrugs: Challenges and Rewards Part 1 2007, Springer. V. Stella, R. Borchard, M. Hageman, R. Oliyai, H. Maag, J. Tilley (Eds.).
139. Fischer J.H., Patel T.V., Fischer P.A. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin. Pharmacokinet. 2003, 42:33-58.
140. Davies J.A. Mechanisms of action of antiepileptic drugs. Seizure 1995, 4:267-271.
141. Gribkoff V.K., Starrett J.E., Dworetzky S.I., Hewawasam P., Boissard C.G., Cook D.A., Frantz S.W., Heman K., Hibbard J.R., Huston K., Johnson G., Krishnan B.S., Kinney G.G., Lombardo L.A., Meanwell N.A., Molinoff P.B., Myers R.A., Moon S.L., Ortiz A., Pajor L., Pieschl R.L., Post-Munson D.J., Signor L.J., Srinivas N., Taber M.T., Thalody G., Trojnacki J.T., Wiener H., Yeleswaram K., Yeola S.W. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat. Med. 2001, 7:471-477.
142. Romine J.L., Martin S.W., Hewawasam P., Meanwell N.A., Gribkoff V.K., Starrett J.E. Dipheyyl oxadazolones as potassium channel modulators 1999, Bristol-Myers Squibb Company. U.S.P. Office (Ed.).
143. Hewawasam P., Ding M., Chen N., King D., Knipe J., Pajor L., Ortiz A., Gribkoff V.K., Starrett J. Synthesis of water-soluble prodrugs of BMS-191011: a maxi-K channel opener targeted for post-stroke neuroprotection. Bioorg. Med. Chem. Lett. 2003, 13:1695-1698.
144. Mori A., Suzuki S., Sakamoto K., Nakahara T., Ishii K. BMS-191011, an opener of large-conductance Ca2+-activated potassium channels, dilates rat retinal arterioles in vivo. Biol. Pharm. Bull. 2011, 34:150-152.
145. Adler C.H. Treatment of restless legs syndrome with gabapentin. Clin. Neuropharmacol. 1997, 20:148-151.
146. Gee N.S., Brown J.P., Dissanayake V.U.K., Offord J., Thurlow R., Woodruff G.N. The novel anticonvulsant drug, Gabapentin (Neurontin), binds to the subunit of a calcium channel. J. Biol. Chem. 1996, 271:5768-5776.
147. McLean M.J. Gabapentin. Epilepsia 1995, 36(Suppl. 2):S73-86.
148. Yaltho T.C., Ondo W.G. The use of gabapentin enacarbil in the treatment of restless legs syndrome. Ther. Adv. Neurol. Disord. 2010, 3:269-275.
149. Cundy K.C., Sastry S., Luo W., Zou J., Moors T.L., Canafax D.M. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J. Clin. Pharmacol. 2008, 48:1378-1388.